Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome.
In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)ACCORD-2 Phase 3 ...
Businessworld6d
wankhede stadium boundary length
New depression drug targeting NMDA receptors reaches primary endpoint in Phase 3 New regulations preview! The first "General ...
Businessworld6d
t20 world cup list india team
INR:1645. t20 world cup list india team Exploring the current status of unprofitable pharmaceutical companies listed in Hong Kong New depression dru ...